Kelli N Burger
Overview
Explore the profile of Kelli N Burger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
599
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bartemes K, Gochanour B, Routman D, Ma D, Doering K, Burger K, et al.
Oral Oncol
. 2023 Sep;
146:106568.
PMID: 37717549
Objective: Early identification of human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) is challenging and novel biomarkers are needed. We hypothesized that a panel of methylated DNA markers (MDMs) found...
12.
Ebner D, Burger K, Mahoney D, Broderick B, Eckmann J, Devens M, et al.
Dig Dis Sci
. 2023 Jul;
68(9):3721-3731.
PMID: 37486445
Background And Aims: Variation in colorectal neoplasia detection limits the effectiveness of screening colonoscopy. By evaluating neoplasia detection rates of individual colonoscopists, we aimed to quantify the effects of pre-procedural...
13.
Bakkum-Gamez J, Sherman M, Slettedahl S, Mahoney D, Lemens M, Laughlin-Tommaso S, et al.
Gynecol Oncol
. 2023 May;
174:11-20.
PMID: 37141817
Objective: Alterations in DNA methylation are early events in endometrial cancer (EC) development and may have utility in EC detection via tampon-collected vaginal fluid. Methods: For discovery, DNA from frozen...
14.
Ebner D, Eckmann J, Burger K, Mahoney D, Whitaker T, Petersen I, et al.
Gastro Hep Adv
. 2022 Sep;
1(5):746-754.
PMID: 36117548
Background And Aims: Multitarget stool DNA (mt-sDNA) is approved for average-risk colorectal cancer screening; test performance in persons with prior radiation therapy (RT) has not been studied. RT can induce...
15.
Majumder S, Taylor W, Foote P, Gysbers B, Cao X, Mahoney D, et al.
Pancreatology
. 2022 Jul;
22(6):770-773.
PMID: 35843766
High-risk individuals (HRIs) with familial and genetic predisposition to pancreatic ductal adenocarcinoma (PDAC) are eligible for screening. There is no accurate biomarker for detecting early-stage PDAC. We previously demonstrated that...
16.
Marinelli L, Kisiel J, Slettedahl S, Mahoney D, Lemens M, Shridhar V, et al.
Gynecol Oncol
. 2022 Apr;
165(3):568-576.
PMID: 35370009
Objective: Aberrant DNA methylation is an early event in carcinogenesis which could be leveraged to detect ovarian cancer (OC) in plasma. Methods: DNA from frozen OC tissues, benign fallopian tube...
17.
Ebner D, Eckmann J, Burger K, Mahoney D, Bering J, Kahn A, et al.
Clin Transl Gastroenterol
. 2021 Jun;
12(6):e00375.
PMID: 34140458
Introduction: Significant variability between colonoscopy operators contributes to postcolonoscopy colorectal cancers (CRCs). We aimed to estimate postcolonoscopy colorectal neoplasia (CRN) detection by multi-target stool DNA (mt-sDNA), which has not previously...
18.
Majumder S, Taylor W, Foote P, Berger C, Wu C, Mahoney D, et al.
Clin Cancer Res
. 2021 Feb;
27(9):2523-2532.
PMID: 33593879
Purpose: We have previously identified tissue methylated DNA markers (MDMs) associated with pancreatic ductal adenocarcinoma (PDAC). In this case-control study, we aimed to assess the diagnostic performance of plasma MDMs...
19.
Xie H, Mahoney D, Foote P, Burger K, Doering K, Taylor W, et al.
Clin Cancer Res
. 2020 Oct;
27(1):141-149.
PMID: 33028593
Purpose: We aimed to assess the concordance of colorectal cancer-associated methylated DNA markers (MDM) in primary and metastatic colorectal cancer for feasibility in detection of distantly recurrent/metastatic colorectal cancer in...
20.
Limburg P, Mahoney D, Ahlquist D, Allawi H, Johnson S, Kaiser M, et al.
Cancer Epidemiol Biomarkers Prev
. 2020 May;
29(8):1570-1576.
PMID: 32467348
Background: Emerging colorectal cancer trends demonstrate increased incidence and mortality in younger populations, prompting consideration of average-risk colorectal cancer screening initiation at age 45 versus 50 years. However, screening test...